TrevenaCompany Review & Valuation

TRVN
Nasdaq
Latest Price
2.62USD
Market Capitalization
256.40mUSD

About Trevena, Inc.

Trevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed PhShow morease III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.Show less

Industry
Biotechnology
HQ Location
Chesterbrook, Pennsylvania
Wikipedia

Stock Price

Price data not available for Trevena.

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

Ovoca Bio
Vernalis
Incyte
Biofrontera

back to top